Geneva Partners’s Bio-Techne TECH Stock Holding History

Geneva Partners’s Portfolio TECH Stock Details TECH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-9,660	Closed	-$638K	–	93
2020 Q2	$638K	Buy	+9,660	New	+$578K	0.45%	47

Other funds holding TECH

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return

BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $3.89B AUM 16.15% 1-Year Est. Return

DDC

DF Dent & Co Baltimore, Maryland $5.27B AUM 7.89% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geneva Partners's TECH Position: Q3 2020 in Review

Geneva Partners sold out of Bio-Techne (TECH) in Q3 2020, closing a stake of 9,660 shares — an estimated $638K sold.

Geneva Partners first reported a position in TECH in Q2 2020 and held it in 1 quarter. The position peaked at $638K in Q2 2020. 418 funds tracked by Wall St. Rank hold TECH as of Q3 2020.

Geneva Partners reported no remaining Bio-Techne position as of Q3 2020 after selling out during the quarter.
Geneva Partners sold 9,660 Bio-Techne shares in Q3 2020, an estimated $638K.
Geneva Partners first reported a position in Bio-Techne in Q2 2020 and held it in 1 quarter.
Geneva Partners's Bio-Techne position peaked at $638K in Q2 2020.
418 funds tracked by Wall St. Rank held Bio-Techne as of Q3 2020.

Based on Geneva Partners's 13F filing for Q3 2020, filed 28 Oct 2020.